What’s your clinical protocol for managing diabetic retinopathy?

News
Article
Optometry Times JournalJanuary digital edition 2024
Volume 16
Issue 01

A task force of eye care providers is asking for feedback on newly-developed guidelines for managing diabetic retinopathy in their patients.

Older man sitting down holding the hand of a physician on his shoulder Image Credit: AdobeStock/BeaunittaVanWyk/peopleimages.com

Image Credit: AdobeStock/BeaunittaVanWyk/peopleimages.com

According to recent projections, by 2060, nearly 18% of US adults (60.6 million) will have diabetes.1 That number is currently 38.4 million.2 Twenty-six percent of them have diabetic retinopathy (DR).3 What’s more, all of those patients are at risk of developing vision-threatening diabetic retinopathy and diabetic macular edema.3 By 2050, the prevalence of DR is predicted to nearly triple4 and, without treatment, the patients with high-risk proliferative DR have a 50% chance of becoming blind within 5 years.3 These figures are concerning and have made me question what I can do to make a difference for the patients who rely on me for primary eye care services.

As I reflected on this while brainstorming with colleagues, I found a group of like-minded leaders in optometry who shared my passion to make a real difference. Together, we formed a task force. The group unanimously agreed that there are unmet needs in diabetic eye care that our profession is uniquely suited to fill. So, we set out with a goal to elevate the standard of care. However, we remain sensitive to the fact that most of our colleagues practice in busy environments, like my own, that can make change difficult. With that in mind, we knew we needed to create a plan that would be practical to implement.

After nearly a year of development, our group of 14 clinicians released a consensus document titled “Modern Fundamentals of Diabetic Retinopathy Management in Optometry.” We believe that this framework will radically simplify DR management so optometrists can confidently care for the growing population of patients with diabetes. Importantly, the guidelines are based on 5 pillars, all of which are backed by evidence-based science. We distributed these for the first time at the 2023 American Academy of Optometry meeting in New Orleans, Louisiana, in October. The support we’ve received has been overwhelmingly positive, but we believe that it is important to solicit feedback from the entire optometric community.

To achieve this, we’ve developed a survey so optometrists can vote on whether they support specific elements of the new guidelines, as listed below. We also have included write-in response areas for comments. We believe this is an important next step in erasing the unmet needs in diabetic eye care. Optometry is at the forefront of this effort, and it is the goal of the task force to ensure that everyone’s voice is heard so a diversity of views are represented and considered as we move forward.

On behalf of my colleagues on the task force, I invite you to take this survey. We look forward to keeping you abreast of the results as we collaborate to erase avoidable blindness due to diabetic retinopathy.

The 5 Pillars of Diabetic Retinopathy Management in Optometry

Detect: Approach diabetic retinopathy as a chronic progressive disease. Being a chronic progressive disease implies that you can detect it before it becomes an advanced disease. This can be achieved using both structural and functional testing.

Grade: Grade diabetic retinopathy at the time of diagnosis and at each subsequent visit. Chart structural retinal damage and quantify retinal cell function.

Assess risk: To assess risk of progression, monitor diabetic retinopathy patients over time using both structural and objective functional measures.

Manage: Utilize multidisciplinary resources to manage all diabetic retinopathy patients, regardless of disease severity.

Support: Provide comprehensive patient education and strategies to help prevent disease progression.

References
  1. Lin J, Thompson TJ, Cheng YJ, et al. Projection of the future diabetes burden in the United States through 2060. Popul Health Metr. 2018;16(1):9. doi:10.1186/s12963-018-0166-4
  2. National Diabetes Statistics Report. Updated November 29, 203. Accessed January 9, 2024. https://www.cdc.gov/diabetes/data/statistics-report/
  3. Lundeen EA, Burke-Conte Z, Rein DB, et al. Prevalence of diabetic retinopathy in the US in 2021. JAMA Ophthalmol. 2023;141(8):747-754. doi:10.1001/jamaophthalmol.2023.2289
  4. Saaddine JB, Honeycutt AA, Narayan KMV, Zhang X, Klein R, Boyle JP. Projection of diabetic retinopathy and other major eye diseases among people with diabetes mellitus: United States, 2005-2050. Arch Ophthalmol. 2008;126(12):1740-1747. doi:10.1001/archopht.126.12.1740
Recent Videos
Nora Lee Cothran, OD, FAAO, details a real-world study that found IOP-lowering benefits when switching patients with glaucoma to latanoprostene bunod treatment.
Mile Brujic, OD, FAAO; Nate Lighthizer, OD, FAAO; Brianna Rhue, OD, FAAO, FSLS; Ben Casella, OD; and Ben Gaddie, OD, FAAO shared their insights from the conference.
Agatha Sleboda, OD; Arti Shah, OD, FAAO; and Kent J. Nozacki, OD provide the best tips that they give to their patients during natural disasters events in light of the recent Greater Los Angeles wildfires.
Optometrists local to the Los Angeles area overview their efforts to continue providing support to patients affected by January's wildfires.
Brianna Rhue, OD, FAAO, FSLS, reviewed key takeaways from The Future of Myopia Management: Perspectives from Leading Experts talk from SECO 2025.
Dr. Julie Rodman discusses retina, imaging, and posterior segment in SECO presentations
Robert L. Stamper, MD, overviews his optometric track talk titled Objective Perimetry - Can you see it? at this year's Glaucoma 360 meeting.
Dr. Julie Rodman previews her SECO presentations
Yvonne Ou, MD, outlined lifestyle modifications for glaucoma management that have proven beneficial, including yoga and cycling.
Robert L. Stamper, MD, weighs in on what he think more optometrists should know about glaucoma and current misconceptions concerning glaucoma testing.
© 2025 MJH Life Sciences

All rights reserved.